RxDoctor Payments Data

Bronwyn Woods, MD

Family Medicine · Oklahoma City, OKNPI 1780627232

Payments from drug & device makers

$9,919in general payments, 2019–2025

Across 697 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$975
  • Boehringer Ingelheim$966
  • AstraZeneca$683
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$9,906100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,919 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$93,719
Medicare patients
198
Services billed
1,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$59,626
JardianceEmpagliflozin38$50,555
OzempicSemaglutide45$41,929
EliquisApixaban52$37,725
RybelsusSemaglutide20$25,786
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,264
Soliqua 100-33Insulin Glargine/Lixisenatide20$20,807
Breo ElliptaFluticasone/Vilanterol32$13,993
Tresiba Flextouch U-100Insulin Degludec24$13,125
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$12,817
FarxigaDapagliflozin Propanediol28$12,717
MyrbetriqMirabegron11$10,184
Combivent RespimatIpratropium/Albuterol Sulfate11$7,964
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,659
Tresiba Flextouch U-200Insulin Degludec12$6,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$975$67,71565 claims
Lilly USA, LLCMounjaro$1,124$59,62647 claims
Boehringer IngelheimJardiance, Combivent Respimat$966$58,51949 claims
PfizerEliquis$1,314$37,72552 claims
GSKTrelegy Ellipta, Breo Ellipta$574$35,25660 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$134$20,80720 claims
AstraZenecaFarxiga, Symbicort$683$19,01941 claims
Astellas Pharma US IncMyrbetriq$144$10,18411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →